BRNS
Barinthus Biotherapeutics plcNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$23.23M
P/E Ratio
—
EPS
$-1.64
Beta
-0.60
52W High
$2.91
52W Low
$0.51
50-Day MA
$0.63
200-Day MA
$0.96
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company is headquartered in Harwell, the United Kingdom.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | -133,000 |
| EBITDA | $-55.22M |
| Operating Margin | 0.00% |
| Return on Equity | -65.00% |
| Return on Assets | -28.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.82 |
| Price-to-Book | 0.33 |
| Price-to-Sales (TTM) | 2.17 |
| EV/Revenue | 0.616 |
| EV/EBITDA | -6.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $40.85M |
| Float | $36.06M |
| % Insiders | 13.37% |
| % Institutions | 40.88% |
Data last updated: 4/7/2026